Tapinarof Cream 1%: First Approval

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Plaque psoriasis is a chronic immune-mediated skin disease.
• Topical treatments are crucial for managing psoriasis.
• The aryl hydrocarbon receptor (AhR) plays a role in immune-mediated skin responses.

Purpose of the Study:

• To summarize the development milestones of tapinarof cream 1%.
• To highlight the approval of tapinarof cream 1% for plaque psoriasis.

Main Methods:

• Review of developmental data for tapinarof cream 1%.
• Analysis of clinical trial outcomes leading to regulatory approval.

Main Results:

• Tapinarof cream 1% (VTAMA®) received US FDA approval in May 2022.
• The cream is a once-daily topical treatment for plaque psoriasis in adults.

Conclusions:

• Tapinarof cream 1% represents a significant advancement in topical psoriasis treatment.
• Further investigation is ongoing for atopic dermatitis treatment.